![]()
|
|
||||||||
J. Biol. Chem., Vol. 266, Issue 30, 20070-20078, Oct, 1991
RJ Mayer, JL Adams, MJ Bossard and TA Berkhout
Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
A 32-carboxylic acid derivative of lanosterol (SKF 104976) was found to be a potent inhibitor of lanosterol 14 alpha-demethylase (14 alpha DM). 14 alpha DM activity in a Hep G2 cell extract was inhibited 50% by 2 nM SKF 104976. Exposure of intact cells to similar concentrations of the compound resulted in the inhibition of incorporation of [14C]acetate into cholesterol with concomitant accumulation of lanosterol as well as a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not effect low density lipoprotein uptake and degradation in Hep G2 cells, suggesting that HMGR and low density lipoprotein receptor activity were not coordinately regulated under these conditions. Reduction of the flux of carbon units in the sterol synthetic pathway by as much as 80% did not alter the suppressing effect of SKF 104976 on HMGR activity. However, under conditions where sterol synthesis was almost completely blocked by lovastatin, HMGR activity was not suppressed by SKF 104976. Mevalonate, at concentrations that did not decrease HMGR activity, was able to restore the inhibiting effect of SKF 104976 on HMGR activity. The rapid inhibition (2-3 h) of HMGR activity by SKF 104976 to 30-60% of the level in controls was not dependent on the initial amount of HMGR enzyme present. These findings suggest that upon inhibition of 14 alpha DM by SKF 104976, a mevalonate-derived precursor regulates HMGR activity, even when the sterol synthetic rate is considerably reduced and when HMGR protein levels are very high. In Hep G2 cells, formation of oxylanostenols from [3H]mevalonate reached a maximum between 1 and 10 nM SKF 104976 and was negligible at higher concentrations. This result suggests that oxylanostenols are not the key mediators of the modulation of HMGR in Hep G2 cells upon 14 alpha DM inhibition.
This article has been cited by other articles:
![]() |
C. Fernandez, M. Martin, D. Gomez-Coronado, and M. A. Lasuncion Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression J. Lipid Res., May 1, 2005; 46(5): 920 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Schroepfer Jr. Oxysterols: Modulators of Cholesterol Metabolism and Other Processes Physiol Rev, January 1, 2000; 80(1): 361 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. MARTÍNEZ-BOTAS, Y. SUÁREZ, A. J. FERRUELO, D. GÓMEZ-CORONADO, and M. A. LASUNCIÓN Cholesterol starvation decreases P34cdc2 kinase activity and arrests the cell cycle at G2 FASEB J, August 1, 1999; 13(11): 1359 - 1370. [Abstract] [Full Text] |
||||
![]() |
R. Gebhardt Inhibition of Cholesterol Biosynthesis in Primary Cultured Rat Hepatocytes by Artichoke (Cynara scolymus L.) Extracts J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1122 - 1128. [Abstract] [Full Text] |
||||
![]() |
T. A. Berkhout, H. M. Simon, D. D. Patel, C. Bentzen, E. Niesor, B. Jackson, and K. E. Suckling The Novel Cholesterol-lowering Drug SR-12813 Inhibits Cholesterol Synthesis via an Increased Degradation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase J. Biol. Chem., June 14, 1996; 271(24): 14376 - 14382. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |